[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564821":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":25,"locations":32,"responsibleParty":78,"collaborators":80,"id":85,"slug":10,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":10,"enrollmentInfo":94,"targetDuration":10,"studyType":97,"phases":10,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study population",null,"The study population must correspond to the research inclusion criteria. A fibroscan will be performed on each patient enrolled in the study. Each participant will also be offered a biological sample for an ancillary study.",[13,14],"Diagnostic Test: Fibroscan","Other: Sample collection",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"DIAGNOSTIC_TEST","Fibroscan","Evaluation of the prevalence of steatosis by measuring ultrasound attenuation with Fibroscan® (non-invasive method, at a distance from a meal (3h fasting)).",[9],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"Sample collection","20 mL whole blood sample",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Sarra SMATI","CONTACT","02 53 48 27 19","+33","sarra.grangeon@chu-nantes.fr",[33,52,63],{"facility":34,"status":35,"city":36,"state":10,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"CHU angers","NOT_YET_RECRUITING","Angers","49933","France",{"type":40,"coordinates":41},"Point",[42,43],-0.55202,47.47156,{"lat":43,"lon":42},[46,50],{"name":47,"role":28,"phone":48,"phoneExt":10,"email":49},"Sandrine LABOUREAU","02 41 35 45 93","sandrine.laboureau@chu-angers.fr",{"name":47,"role":51,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":53,"status":54,"city":55,"state":10,"zip":10,"country":38,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"CHU Nantes","RECRUITING","Nantes",{"type":40,"coordinates":57},[58,59],-1.55336,47.21725,{"lat":59,"lon":58},[62],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},{"facility":64,"status":35,"city":65,"state":10,"zip":66,"country":38,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Rennes University Hospital","Rennes","35033",{"type":40,"coordinates":68},[69,70],-1.67431,48.11109,{"lat":70,"lon":69},[73,77],{"name":74,"role":28,"phone":75,"phoneExt":10,"email":76},"François PAILLARD, Dr","02.99.28.25.40","francois.paillard@chu-rennes.fr",{"name":74,"role":51,"phone":10,"phoneExt":10,"email":10},{"type":79,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[81,84],{"name":82,"class":83},"University Hospital, Angers","OTHER_GOV",{"name":64,"class":6},"100564821",false,"NCT06634160","Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia","Assessment of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) Prevalence in Patients With Heterozygous Familial Hypercholesterolemia (HeFH): the STEATO-FH Study","STEATO-FH","Inclusion Criteria:\n\n* Patient aged 35 or over\n* Consultation at Nantes, Rennes or Angers University Hospital during the inclusion period\n* With a diagnosis of familial hypercholesterolemia defined by the presence of a genetic variant, ACMG classes 4 \\& 5 on LDLR, APOB or PCSK9\n* Patient not objecting to inclusion in study (no written objection)\n\nExclusion Criteria:\n\n* Protected patients: minors, adults under guardianship, curatorship and\u002For safeguard of justice\n* Pregnant or breast-feeding\n* Active viral hepatitis\n* Hemochromatosis\n* Other genetic or autoimmune hepatitis\n* Current treatment with a drug likely to cause hepatic steatosis, including amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals\n* Current oral corticosteroid therapy unless dose has been stable for ≥ 3 months\n* Current pathological alcohol consumption (≥ 60 g\u002Fday in men and ≥ 50 g\u002Fday in women)","ALL","35 Years",{"count":95,"type":96},200,"ESTIMATED","OBSERVATIONAL","The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population.",[100],"Heterozygous Familial Hypercholesterolemia",[102,100,103,104],"MASLD","steatosis","fibrosis","2025-02-05",{"date":107,"type":108},"2025-02-06","ACTUAL",{"date":110,"type":108},"2025-01-30",{"date":112,"type":96},"2028-01-30",{"name":5,"class":6},3]